КЛК 'Владминес'
22 Апрель 2024, 17:21:49 *
Добро пожаловать, Гость. Пожалуйста, войдите или зарегистрируйтесь.
Войти
Лучшие фелинологические организации!
Добавье свою организацию! пока бесплатно!!!
Новости: На сайте работает раздел Наши чемпионы! Все чемпионы и чемпионки семейства кошачьих :)
 
   Начало   Помощь Поиск Календарь Галерея  
Страниц: [1]
  Печать  
Автор Тема: Comparative efficacy and safety of topical hemostatic agents  (Прочитано 2872 раз)
0 Пользователей и 1 Гость смотрят эту тему.
upamfva
Ветеран
********

Кошачьих сил: 137
upamfva is awe-inspiring!upamfva is awe-inspiring!upamfva is awe-inspiring!upamfva is awe-inspiring!upamfva is awe-inspiring!upamfva is awe-inspiring!upamfva is awe-inspiring!upamfva is awe-inspiring!upamfva is awe-inspiring!upamfva is awe-inspiring!upamfva is awe-inspiring!upamfva is awe-inspiring!
Offline Offline

Сообщений: 2338

Благодарности
-Выражено: 0
-Получено: 0


Просмотр профиля Email
« : 11 Май 2023, 08:39:30 »

Comparative efficacy and safety of topical hemostatic agents




Topical hemostatic agents are commonly used for reducing perioperative blood loss and transfusion requirement in primary total knee arthroplasty (TKA), although the optimal option has yet to be defined. This study aimed to evaluate the efficacy and safety of topical hemostatic agents and rank the best intervention using the network meta-analysis (NMA) method.To get more news about advanced hemostatic agents, you can visit rusuntacmed.com official website.

Methods: We searched Web of science, PubMed, and Cochrane Library database up to April 2020, for randomized controlled trials (RCTs) on topical hemostatic agents in primary TKA. The quality of included studies was assessed using the Cochrane “risk of bias” tool. Direct and indirect comparisons were performed for the result of network meta-analysis followed by consistency test.
Results: Thirty seven RCTs with 3792 patients were included in this NMA and the pooled results indicated that tranexamic acid plus diluted epinephrine (TXA+DEP) displayed the highest efficacy in reducing total blood loss, hemoglobin drop and transfusion requirement. None of the included treatments was found to increase risk of thromboembolic events compared to placebo. According to the results of ranking probabilities, TXA+DEP had the highest possibility to be the best topical hemostatic agent with regard to the greatest comparative efficacy and a relatively high safety level.

Conclusion: Current evidence supports that administration of TXA+DEP may be the optimal topical hemostatic agent to decrease blood loss and transfusion requirement in primary TKA. More direct studies that focused on the topical application of TXA+DEP versus other treatments are needed in the future.
Записан
Страниц: [1]
  Печать  
 
Перейти в:  

Powered by MySQL Powered by PHP Powered by SMF 1.1.11 | SMF © 2006, Simple Machines LLC Valid XHTML 1.0! Valid CSS!